Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

NCT04526691 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT04526691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04526691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 15, 2020
Completion date
December 31, 2026
Enrollment
145 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic nsclc